{"entity":{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","aka":["Jules Bordet Institute","Bordet","Hôpital Universitaire de Bruxelles"],"tldr":"Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.","summary":"The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Institut_Jules_Bordet","links":[{"label":"Homepage","url":"https://www.bordet.be"},{"label":"Breast International Group","url":"https://www.bigagainstbreastcancer.org"}],"tags":[],"related":[],"indications":["breast-her2-positive","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.813,"lng":4.265,"institutionType":"cancer-center","website":"https://www.bordet.be","university":"Université libre de Bruxelles","programs":["Breast International Group","Breast cancer genomics and ctDNA","Early-phase trials","Haematology","Nuclear medicine"]},"route":"/institutions/institut-jules-bordet/","neighbours":{"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}